Reslizumab (Cinqair)
Asthma is a common chronic respiratory disorder characterized by reversible airway obstruction, pulmonary inflammation, airway hyper-responsiveness, and airway remodelling.1,2 Patients with asthma typically present with paroxysmal or persistent symptoms of wheezing, dyspnea, chest tightness, sputum...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, 2017
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references